BRPI0813680A2 - AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO. - Google Patents

AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.

Info

Publication number
BRPI0813680A2
BRPI0813680A2 BRPI0813680-7A2A BRPI0813680A BRPI0813680A2 BR PI0813680 A2 BRPI0813680 A2 BR PI0813680A2 BR PI0813680 A BRPI0813680 A BR PI0813680A BR PI0813680 A2 BRPI0813680 A2 BR PI0813680A2
Authority
BR
Brazil
Prior art keywords
well
pharmaceutical composition
same
irna agents
composition understanding
Prior art date
Application number
BRPI0813680-7A2A
Other languages
English (en)
Inventor
Gino Van Heeke
Emma Hickman
Henry Luke Danahay
Pamela Tan
Anke Geick
Hans-Peter Vornlacher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0813680A2 publication Critical patent/BRPI0813680A2/pt
Publication of BRPI0813680B1 publication Critical patent/BRPI0813680B1/pt
Publication of BRPI0813680A8 publication Critical patent/BRPI0813680A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0813680A 2007-06-15 2008-06-13 composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso BRPI0813680A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07110376 2007-06-15
EP07110376.6 2007-06-15
EP07114265 2007-08-13
EP07114265.7 2007-08-13
PCT/EP2008/057476 WO2008152131A2 (en) 2007-06-15 2008-06-13 Rnai inhibition of alpha-enac expression

Publications (3)

Publication Number Publication Date
BRPI0813680A2 true BRPI0813680A2 (pt) 2015-01-06
BRPI0813680B1 BRPI0813680B1 (pt) 2018-02-06
BRPI0813680A8 BRPI0813680A8 (pt) 2018-08-28

Family

ID=40130244

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813680A BRPI0813680A8 (pt) 2007-06-15 2008-06-13 composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso

Country Status (26)

Country Link
US (12) US7718632B2 (pt)
EP (7) EP2223692B1 (pt)
JP (6) JP5485146B2 (pt)
KR (2) KR101653008B1 (pt)
CN (1) CN101778941B (pt)
AR (1) AR066984A1 (pt)
AU (1) AU2008263876B2 (pt)
BR (1) BRPI0813680A8 (pt)
CA (1) CA2690674C (pt)
CL (1) CL2008001756A1 (pt)
CO (1) CO6251331A2 (pt)
CR (1) CR11136A (pt)
CU (1) CU23774A3 (pt)
EA (1) EA200901653A1 (pt)
EC (1) ECSP099794A (pt)
ES (6) ES2432532T3 (pt)
GT (1) GT200900315A (pt)
IL (1) IL202366A0 (pt)
MA (1) MA31564B1 (pt)
MX (1) MX2009013609A (pt)
PE (1) PE20090942A1 (pt)
SG (3) SG10201404955RA (pt)
SV (1) SV2009003434A (pt)
TN (1) TN2009000521A1 (pt)
TW (3) TWI444474B (pt)
WO (1) WO2008152131A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4709545B2 (ja) * 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
KR100473148B1 (ko) * 2002-11-27 2005-03-10 (주)텔리언 버스트모드 패킷 전달을 위한 정합장치 및 방법
EP1796732B1 (en) * 2004-10-01 2013-10-30 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
KR20110095391A (ko) * 2008-11-26 2011-08-24 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 상피 나트륨 채널 (ＥＮａＣ) 유전자 발현의 ＲＮＡ 간섭 매개 억제
US8563710B2 (en) 2009-04-03 2013-10-22 Biomics Biotechnologies Co., Ltd. Modified oligonucleotide and its preparation and application
CN103275978B (zh) * 2009-04-03 2014-10-29 百奥迈科生物技术有限公司 修饰的小干扰核酸及其制备方法
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
US20120207818A1 (en) * 2009-07-14 2012-08-16 Shinohara Fumikazu Composition for suppressing expression of target gene
AU2010306940A1 (en) * 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
MX339050B (es) 2009-12-18 2016-05-09 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
CA3098080A1 (en) * 2010-04-23 2011-10-27 Arrowhead Research Corporation Organic compositions to treat beta-enac-related diseases
US8916352B2 (en) * 2011-04-08 2014-12-23 Bio-Rad Laboratories, Inc. PCR reaction mixtures with decreased non-specific activity
CN104271740A (zh) 2011-04-20 2015-01-07 L·J·史密斯 利用在细胞中自组装和产生RNAi活性的成分来调节基因表达的方法和组合物
EP2723756B1 (en) * 2011-06-21 2020-03-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
US20160032284A1 (en) 2011-09-02 2016-02-04 Arrowhead Research Corportation Organic compositions to treat hsf1-related diseases
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
AU2017354041B2 (en) 2016-11-01 2024-02-01 Arrowhead Pharmaceuticals, Inc. Alpha-V beta-6 integrin ligands and uses thereof
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
MX2020003554A (es) * 2017-10-31 2020-08-03 Ionis Pharmaceuticals Inc Moduladores de la expresion de enac.
SG11202002967SA (en) * 2017-11-01 2020-05-28 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
WO2021041776A1 (en) * 2019-08-30 2021-03-04 United States Government As Represented By The Department Of Veterans Affairs Liposomal troponoid compound formulations
TW202130809A (zh) 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
US12415840B2 (en) 2020-02-21 2025-09-16 Brookhaven Science Associates, Llc Modified form of oleosin that when expressed in plants leads to increased triacylglycerol (oil) accumulation
WO2022216920A1 (en) 2021-04-08 2022-10-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
US11957178B2 (en) 2021-11-15 2024-04-16 Apackaging Group Llc Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3604625C2 (de) * 1986-02-14 1994-01-20 Bmw Rolls Royce Gmbh Gasturbine
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5451670A (en) * 1987-12-09 1995-09-19 City Of Hope Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
AU6044994A (en) 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
CA2137297C (en) 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (ja) * 1994-01-24 2004-07-14 日本油脂株式会社 点火薬造粒物の製造方法
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
ATE247971T1 (de) 1995-08-01 2003-09-15 Novartis Erfind Verwalt Gmbh Liposomale oligonukleotidzusammensetzungen
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) * 1996-08-01 1999-02-02 Wilson-Hyde; Cynthia Step aerobic platform
EP0975798A1 (en) * 1997-03-11 2000-02-02 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5976849A (en) 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20030064385A1 (en) 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
EP1478655A4 (en) 2001-12-31 2006-05-10 Algos Therapeutics Inc METHODS AND SUBSTANCES FOR ENAC-BETA MODULATION
JP4709545B2 (ja) * 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20060275770A1 (en) 2002-11-27 2006-12-07 Daniel Bednarik Heart failure gene determination and therapeutic screening
AU2002368410A1 (en) 2002-11-29 2004-06-23 Basf Aktiengesellschaft Methods for the production of methionine
DE10305213A1 (de) 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
WO2004089423A2 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Pharmico-gene theraphy of epithelial sodium channel associated disoders
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4530335B2 (ja) * 2004-02-03 2010-08-25 独立行政法人科学技術振興機構 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
SE0402832D0 (sv) * 2004-11-18 2004-11-18 Astrazeneca Ab Methods
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
EP1824872B1 (en) * 2004-12-14 2012-02-08 Alnylam Pharmaceuticals Inc. Rnai modulation of mll-af4 and uses thereof
EP1948674A4 (en) * 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
US20070149456A1 (en) * 2005-12-13 2007-06-28 University Of Pittsburgh Epithelial sodium channel inhibiting agents and uses therefor
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
US20110150897A1 (en) 2006-10-11 2011-06-23 Meyer Thomas F Influenza targets
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

Also Published As

Publication number Publication date
US20220235361A1 (en) 2022-07-28
JP2014129373A (ja) 2014-07-10
SG169988A1 (en) 2011-04-29
US20100210513A1 (en) 2010-08-19
TW200911989A (en) 2009-03-16
EP2224004A1 (en) 2010-09-01
US7939508B2 (en) 2011-05-10
US11208662B2 (en) 2021-12-28
BRPI0813680A8 (pt) 2018-08-28
ES2432157T3 (es) 2013-12-02
US7943592B2 (en) 2011-05-17
US10544418B2 (en) 2020-01-28
GT200900315A (es) 2011-10-05
SG10201601846VA (en) 2016-04-28
EP2224005B1 (en) 2013-09-11
MA31564B1 (fr) 2010-08-02
US20150284726A1 (en) 2015-10-08
US8119612B2 (en) 2012-02-21
BRPI0813680B1 (pt) 2018-02-06
EP2223692B1 (en) 2013-07-24
US20100216971A1 (en) 2010-08-26
TW201524510A (zh) 2015-07-01
CA2690674C (en) 2018-09-11
ES2439277T3 (es) 2014-01-22
EA200901653A1 (ru) 2010-06-30
US20090156529A1 (en) 2009-06-18
IL202366A0 (en) 2011-08-01
US9914927B2 (en) 2018-03-13
EP2223693B1 (en) 2013-07-24
US20100210514A1 (en) 2010-08-19
EP2224005A1 (en) 2010-09-01
JP2010530369A (ja) 2010-09-09
KR101653008B1 (ko) 2016-08-31
AU2008263876A1 (en) 2008-12-18
JP6680728B2 (ja) 2020-04-15
EP2223695B1 (en) 2013-07-24
ES2432644T3 (es) 2013-12-04
JP2022188234A (ja) 2022-12-20
CR11136A (es) 2010-01-20
CA2690674A1 (en) 2008-12-18
ES2432532T3 (es) 2013-12-04
US8168606B2 (en) 2012-05-01
EP2223695A1 (en) 2010-09-01
TWI444474B (zh) 2014-07-11
WO2008152131A3 (en) 2009-05-28
ECSP099794A (es) 2010-01-29
CU23774A3 (es) 2012-02-15
TWI552753B (zh) 2016-10-11
KR101821081B1 (ko) 2018-01-23
JP6193906B2 (ja) 2017-09-06
US20160376599A1 (en) 2016-12-29
TWI629063B (zh) 2018-07-11
US9476052B2 (en) 2016-10-25
AR066984A1 (es) 2009-09-23
ES2432158T3 (es) 2013-12-02
SG10201404955RA (en) 2014-10-30
EP2223694B1 (en) 2013-07-24
JP5719047B2 (ja) 2015-05-13
EP2171059A2 (en) 2010-04-07
EP2223693A1 (en) 2010-09-01
MX2009013609A (es) 2010-01-20
CN101778941A (zh) 2010-07-14
CN101778941B (zh) 2013-05-22
PE20090942A1 (es) 2009-08-05
SV2009003434A (es) 2011-03-23
EP2223694A1 (en) 2010-09-01
JP2017222704A (ja) 2017-12-21
US20180148726A1 (en) 2018-05-31
KR20160105530A (ko) 2016-09-06
JP7157775B2 (ja) 2022-10-20
CO6251331A2 (es) 2011-02-21
US20100216972A1 (en) 2010-08-26
EP2223692A1 (en) 2010-09-01
CL2008001756A1 (es) 2009-02-20
TW201636027A (zh) 2016-10-16
JP5485146B2 (ja) 2014-05-07
ES2432643T3 (es) 2013-12-04
KR20100039335A (ko) 2010-04-15
US20220112505A1 (en) 2022-04-14
TN2009000521A1 (en) 2011-03-31
EP2224004B1 (en) 2013-07-24
US7718632B2 (en) 2010-05-18
JP2020094063A (ja) 2020-06-18
US20200157550A1 (en) 2020-05-21
US20100190714A1 (en) 2010-07-29
US9074212B2 (en) 2015-07-07
WO2008152131A2 (en) 2008-12-18
AU2008263876B2 (en) 2012-04-12
JP2015145393A (ja) 2015-08-13

Similar Documents

Publication Publication Date Title
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
SI1998783T1 (sl) Oftalmični sestavki, ki obsegajo providon-jod
HUE042286T2 (hu) Tûvel szerelt, elõre töltött belövõ fecskendõ
BRPI0718266A2 (pt) Compostos heterocíclicos como agentes anti-inflamatórios.
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0815979A2 (pt) compostos e composições com inibidores de quinase, bem como uso dos mesmos
BRPI0921389A2 (pt) seringa de um só uso, de inutilização automática
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI0821668A2 (pt) Uso
HRP20150107T1 (xx) Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
BRPI0813908A2 (pt) Seringa com mecanismo de desativar
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0808172A2 (pt) Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0810654A2 (pt) Tiadiazoliloxifenilamidinas e o seu uso como fungicidas.
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0811444A2 (pt) Derivados de azetidina e seu uso como antagonistas da prostaglandina e2.
BRPI0813453A2 (pt) 3-ciclopropil-4-(3-tiobenzoil)pirazol e seu uso como herbicida.
BRPI0816679A2 (pt) Derivados de ftalazinona.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BRPI0916702A2 (pt) composto, uso de um composto, e, composição farmacêutica.
FR2923713B1 (fr) Composition reductrice epaissie.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2831 DE 08-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.